BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wang H, Marchal G, Ni Y. Multiparametric MRI biomarkers for measuring vascular disrupting effect on cancer. World J Radiol 2011; 3(1): 1-16 [PMID: 21286490 DOI: 10.4329/wjr.v3.i1.1] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
Number Citing Articles
1 Liu Y, Wang S, Zhao X, Feng Y, Bormans G, Swinnen J, Oyen R, Huang G, Ni Y, Li Y. Predicting Clinical Efficacy of Vascular Disrupting Agents in Rodent Models of Primary and Secondary Liver Cancers: An Overview with Imaging-Histopathology Correlation. Diagnostics (Basel) 2020;10:E78. [PMID: 32024029 DOI: 10.3390/diagnostics10020078] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
2 Gabrielson K, Maronpot R, Monette S, Mlynarczyk C, Ramot Y, Nyska A, Sysa-Shah P. In Vivo Imaging With Confirmation by Histopathology for Increased Rigor and Reproducibility in Translational Research: A Review of Examples, Options, and Resources. ILAR J. 2018;59:80-98. [PMID: 30541081 DOI: 10.1093/ilar/ily010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
3 Lee IJ, Lee M, Kim SJ, Kim YK, Won JY, Chung JW. Chemoembolization with Vascular Disrupting Agent CKD-516 Dissolved in Ethiodized Oil in Combination with Doxorubicin: A VX2 Tumor Model Study. Journal of Vascular and Interventional Radiology 2018;29:1078-84. [DOI: 10.1016/j.jvir.2018.03.016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
4 Liu Y, De Keyzer F, Wang Y, Wang F, Feng Y, Chen F, Yu J, Liu J, Song S, Swinnen J, Bormans G, Oyen R, Huang G, Ni Y. The first study on therapeutic efficacies of a vascular disrupting agent CA4P among primary hepatocellular carcinomas with a full spectrum of differentiation and vascularity: Correlation of MRI-microangiography-histopathology in rats. Int J Cancer 2018;143:1817-28. [PMID: 29707770 DOI: 10.1002/ijc.31567] [Cited by in Crossref: 9] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
5 Ham SJ, Choi Y, Lee SI, Kim J, Kim YI, Chung JW, Kim KW. Enhanced efficacy of radiofrequency ablation for hepatocellular carcinoma using a novel vascular disrupting agent, CKD-516. Hepatol Int 2017;11:446-51. [PMID: 28721452 DOI: 10.1007/s12072-017-9811-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
6 Ramot Y, Schiffenbauer YS, Amouyal N, Ezov N, Steiner M, Izrael M, Lavon N, Hasson A, Revel M, Nyska A. Compact MRI for the detection of teratoma development following intrathecal human embryonic stem cell injection in NOD-SCID mice. Neurotoxicology 2017;59:27-32. [PMID: 28069364 DOI: 10.1016/j.neuro.2017.01.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
7 García-Figueiras R, Padhani AR, Baleato-González S. Therapy Monitoring with Functional and Molecular MR Imaging. Magn Reson Imaging Clin N Am 2016;24:261-88. [PMID: 26613885 DOI: 10.1016/j.mric.2015.08.003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
8 Liu Y, Yin T, Feng Y, Cona MM, Huang G, Liu J, Song S, Jiang Y, Xia Q, Swinnen JV. Mammalian models of chemically induced primary malignancies exploitable for imaging-based preclinical theragnostic research. Quant Imaging Med Surg. 2015;5:708-729. [PMID: 26682141 DOI: 10.3978/j.issn.2223-4292.2015.06.01] [Cited by in F6Publishing: 32] [Reference Citation Analysis]
9 Yao N, Gao M, Ren K, Jiang X, Li Y, Jiang C, Huang D, Liu W, Wang X, Fang Z, Sun Z, Zhang J, Ni Y. PD806: a novel oral vascular disrupting agent shows antitumor and antivascular effects in vitro and in vivo. Anti-Cancer Drugs 2015;26:148-59. [DOI: 10.1097/cad.0000000000000168] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
10 Joo I, Lee JM, Han JK, Choi BI. Intravoxel incoherent motion diffusion-weighted MR imaging for monitoring the therapeutic efficacy of the vascular disrupting agent CKD-516 in rabbit VX2 liver tumors. Radiology. 2014;272:417-426. [PMID: 24697148 DOI: 10.1148/radiol.14131165] [Cited by in Crossref: 61] [Cited by in F6Publishing: 68] [Article Influence: 7.6] [Reference Citation Analysis]
11 Li J, Chen F, Feng Y, Cona MM, Yu J, Verbruggen A, Zhang J, Oyen R, Ni Y. Diverse responses to vascular disrupting agent combretastatin a4 phosphate: a comparative study in rats with hepatic and subcutaneous tumor allografts using MRI biomarkers, microangiography, and histopathology. Transl Oncol. 2013;6:42-50. [PMID: 23418616 DOI: 10.1593/tlo.12367] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
12 Li J, Oyen R, Verbruggen A, Ni Y. Small Molecule Sequential Dual-Targeting Theragnostic Strategy (SMSDTTS): from Preclinical Experiments towards Possible Clinical Anticancer Applications. J Cancer 2013;4:133-45. [PMID: 23412554 DOI: 10.7150/jca.5635] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
13 Kim KW, Lee JM, Jeon YS, Lee IJ, Choi Y, Park J, Kiefer B, Kim C, Han JK, Choi BI. Vascular disrupting effect of CKD-516: preclinical study using DCE-MRI. Invest New Drugs. 2013;31:1097-1106. [PMID: 23299389 DOI: 10.1007/s10637-012-9915-6] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
14 Lee JM, Yoon JH, Kim KW. Diagnosis of hepatocellular carcinoma: newer radiological tools. Semin Oncol. 2012;39:399-409. [PMID: 22846858 DOI: 10.1053/j.seminoncol.2012.05.010] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 4.6] [Reference Citation Analysis]
15 Burrell JS, Walker-samuel S, Baker LC, Boult JK, Jamin Y, Ryan AJ, Waterton JC, Halliday J, Robinson SP. Evaluation of novel combined carbogen USPIO (CUSPIO) imaging biomarkers in assessing the antiangiogenic effects of cediranib (AZD2171) in rat C6 gliomas. Int J Cancer 2012;131:1854-62. [DOI: 10.1002/ijc.27460] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
16 Wang H, Miranda Cona M, Chen F, Li J, Yu J, Feng Y, Peeters R, De Keyzer F, Marchal G, Ni Y. Comparison between nonspecific and necrosis-avid gadolinium contrast agents in vascular disrupting agent-induced necrosis of rodent tumors at 3.0T. Invest Radiol. 2011;46:531-538. [PMID: 21577133 DOI: 10.1097/rli.0b013e31821a2116] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]